Last reviewed · How we verify
FB102
FB102 is a small molecule that targets the SGLT2 receptor.
FB102 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | FB102 |
|---|---|
| Sponsor | Forte Biosciences, Inc. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
FB102 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata. (PHASE1)
- A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo (PHASE1)
- Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FB102 CI brief — competitive landscape report
- FB102 updates RSS · CI watch RSS
- Forte Biosciences, Inc. portfolio CI